Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

cts receive Traficet-EN. Patients who achieve a pre-specified reduction in disease severity are re-randomized to active drug or placebo for an additional 36-week 'Maintenance Period', thereby permitting an evaluation of the drug's ability to maintain a treatment response.

Traficet-EN is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells to migrate to the digestive tract in a process that ultimately results in the persistent inflammation underlying the disease. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system.

About Traficet-EN(TM) (CCX282-B)

Traficet-EN is a small molecule, orally-available drug that is administered in capsule form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in models of Crohn's disease and ulcerative colitis. In addition to the ongoing PROTECT-1 clinical trial in Crohn's disease, Traficet-EN is being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role. ChemoCentryx has completed five Phase I clinical trials and one four-week Phase II Crohn's disease trial of Traficet-EN, demonstrating that the product candidate is well-tolerated and appropriate for once-daily oral dosing. Traficet-EN may offer advantages
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) ... to successfully open a patient,s blocked artery with a ... drill" to painlessly remove the plaque buildup which causes ... – conducted Wednesday by CVI Director of Endovascular Medicine ...
... HistoRx, the leader in quantitative immunohistochemistry, advances ... recent issuance of US patents covering key features ... results.  The U.S. Patent and Trademark Office has ... for standardization of digital microscopy instruments, methods required ...
Cached Medicine Technology:DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 2DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 3HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 2HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 3
(Date:7/13/2014)... MillionaireCasket.com is a professional supplier of funeral products. According to ... well in the global market. Recently, the company has announced ... a special offer for all the newly released items. ... caskets are made with superb materials. As is commonly noted, ... respect to the departed saint. MillionaireCasket.com is always here to ...
(Date:7/13/2014)... 13, 2014 Intraocular Lens (IOL) Market: ... 2013 - 2019 , Intraocular lens (IOL) is inserted ... or cataracts. The lenses are inserted inside the eye, ... intraocular lens replaces the focusing power of natural lens. ... lens to deliver the light focusing function which was ...
(Date:7/13/2014)... Victorian Hotel has recently announced that ... of bikes for its "Cycle the City" program, which ... tour the area using a rental bicycle, available for ... to call Vancouver home, as it is a city ... picturesque journeys through the countryside. Vancouver hotel rooms often ...
(Date:7/13/2014)... additives are chemicals, which are added to various fuels ... on, in order to enhance their performance. Fuel additives ... by fuels and improving the combustion properties of fuels. ... scale in the long run, but, in the short ... products. , The various fuel additive types include deposit ...
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a ... to 12 years of age that offers everything from gymnastics, ... Summer Camps, is now under new ownership. , Kevin Berry ... spending over six years at The Little Gym of Bellaire ... Berry has over ten years of experience working with children, ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2
... ... received its first batch of Spirits Bay Manuka Honey tested for activity using ... is a registered trademark of the University of Waikato, home of the Honey ... of manuka honey. Produced by a Maori-owned apiary in a remote area of ...
... ... employee wellness programs , ... GA (Vocus) April 7, 2010 -- R. Shane Jackson, president of LocumTenens.com and ... for Health Transformation,s (CHT) first member meeting of 2010, which took place on March 25 ...
... poor people have higher death rates than rich within first decade ... more likely to die within five to 10 years after heart ... 15,156 white men, 6,932 white women, 678 black men and 564 ... and 2005 and found that the poorest patients were 19 to ...
... , ... today released version 4.3 of Replay, the award-winning, next generation backup and disaster recovery ... ... 4.3 of Replay, the award-winning, next generation backup and disaster recovery software solution. ...
... a means of heterosexual interaction on university campuses, more women ... women rate hooking up above dating. Both genders however perceive ... Bradshaw from James Madison University in Virginia, US, and colleagues ... hook up or to date, as well as the perceived ...
... vaccine were at higher risk, study found, but that ... (HealthDay News) The traditional seasonal flu vaccine may ... swine flu, according to the results of four new ... researchers used an ongoing sentinel monitoring system to assess ...
Cached Medicine News:Health News:Koru Naturals Becomes the First U.S. Company to Import Molan Gold Standard Manuka Honey 2Health News:R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting 2Health News:R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting 3Health News:Poor More Likely to Die Following Heart Surgery 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 3Health News:Hooking up or dating: Who benefits? 2Health News:Did 'Regular' Flu Shot Up Risks for H1N1 Flu? 2
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
Freedom Clear® SS Sport Sheath is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath designed for everyday wear. Its brief sheath minimizes roll at the base of the p...
The UltraFlex® all silicone self-adhering male external catheter is 100% latex-free and eliminates the risk of latex-related skin irritations. This breathable catheter promotes healthy skin and i...
... all-silicone Foley catheters eliminate patient exposure ... catheter designs. As an inert, toxin-free ... a safe, dependable Foley catheter. Unlike ... catheters will not leach chemicals or ...
Medicine Products: